A novel approach to anticancer therapies for prostate cancer: Lipoxygenase as a new target in the treatment of prostate cancer

Drugs of the Future

Volumn 30, Issue 4, 2005, Pages 351-357

  Yoshimura, Rikio ^a   Matsuyama, Masahide ^a   Kuratsukuri, Katsuyuki ^a   Tsuchida, Kenji ^a   Takemoto, Yoshiaki ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; ANDROGEN RECEPTOR; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BAICALEIN; CAFFEIC ACID; CASPASE 3; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; JANUS KINASE; KERATINOCYTE GROWTH FACTOR; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; SOMATOMEDIN C; STAT PROTEIN; SULINDAC; VITAMIN D;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG TUMOR; MALE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

EID: 21744457438     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.04.900374     Document Type: Review

References (39)

1. Oh, W.K., Kantoff, P.W. Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 1998, 160: 1220-9.
2. Bosari, S., Lee, A.K., DeLellis, R.A. et al. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992, 23: 755-61.
3. Isaacs, J.T. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999, 26: 263-73.
4. Linja, M.J., Savinainen, K.J., Saramaki, O.R. Amplification and overexpression of androgen receptor gene in hormone refractory prostate cancer. Cancer Res 2001, 61: 3550-5.
5. Culig, Z., Hobisch, A., Cronauer, M.V. et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 54: 5474-8.
6. Craft, N.A., Shostak, Y., Carey, M. et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the Her-2/neu tyrosine kinase. Nat Med 1999, 5: 280-5.
7. Nazareth, L.V., Weigel, N.L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996, 271: 19900-7.
8. Sadar, M.D. Androgen-independent induction of prostate-specific antigen gene expression via crosstalk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999, 274: 7777-83.
9. Yen, S., Lin, H.-K., Kang, H.-Y. et al. From the Her-2/neu signal cascade to androgen receptor and its co-activators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999, 96: 5458-63.
10. Putz, T., Culig, Z., Eder, I.E. et al. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor 1, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999, 59: 227-33.
11. Lou, W., Ni, Z., Dyer, K. et al. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat 3 signaling pathway. Prostate 2000, 42: 239-42.
12. Giardiello, F.M., Hamilton, S.R., Krush, A.J. et al. Treatment of clonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 1993, 1313-6.
13. Sigal, E. The molecular biology of mammalian arachidonic acid metabolism. Am J Physiol 1991, 260: 13-28.
14. Funk, C.D. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1996, 11: 65-84.
15. Brash, A.R. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999, 274: 23679-82.
16. Timar, J., Raso, E., Dome, B. et al. Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 2000, 87: 37-43.
17. Chopra, H., Timar, J., Chen, Y.Q. et al. The lipoxygenase metabolite 12 (S)-HETE induces a cytoskeleton-dependent increase in surface expression of integrin alphaIIbbeta3 on melanoma cells. Int J Cancer 1991, 49: 774-86.
18. Liu, B., Khan, W.A., Hannun, Y.A. et al. 12 (S)-Hydroxyeicostetraenoic acid and 13 (S) hydroxyoctadecadienoic acid regulation of protein kinase C-a in melanoma cells: Role of receptor-mediated hydrolysis of inositol phospholipids. Proc Natl Acad Sci USA 1995, 26: 9323-7.
19. Honn, K.V., Nelson, K.K., Renaud, C. et al. Fatty acid modulation of tumor cell adhesion to microvessel endothelium and experimental metastasis. Prostaglandins 1992, 44: 413-29.
20. Nie, D., Hillman, G.G., Geddes, T. et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 1998, 58: 4047-51.
21. Timar, J., Chen, Y.Q., Liu, B., Bazaz, R. et al. The lipoxygenase metabolite 12 (S)-HETE promotes alphaIIbbeta3 integrin-mediated tumor-cell spreading on fibronectin. Int J Cancer 1992, 52: 594-603.
22. Steele, V.E., Holmes, C.A., Hawk, E.T. et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999, 8: 467-83.
23. Needleman, P., Truk, J., Jakschik, B.A. et al. Arachidonic acid metabolism. Annu Rev Biochem 1986, 55: 69-102.
24. Tsukada, T., Nakashima, K., Shirakawa, S. Arachidonate 5-lipoxygenase inhibitors show potent antiproliferative effects of human leukemia cell lines. Biochem Biophys Res Commun 1986, 140: 832-6.
25. Avis, I.M., Jett, M., Boyle, T. et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996, 97: 806-13.
26. Ghosh, J., Myers, C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 1998, 95: 13182-7.
27. Soriano, A.F., Helfrich, B., Chan, D.C. et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999, 59: 6178-84.
28. Ding, X.Z., Iversen, P., Cluck, M.W. et al. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 1999, 261: 218-23.
29. Nappez, C., Liagre, B., Beneytout, J.L. Changes in lipoxygenase activities in human erythroleukemia (HEL) cells during diosgenin-induced differentiation. Cancer Lett 1995, 96: 133-40.
30. Timar, J., Silletti, S., BazarRaz, A. et al. Regulation of melanoma cell motility by the lipoxgenase metabolite 12-(S)-HETE. Int J Cancer 1993, 55: 1003-10.
31. Nie, D., Tang, K., Diglio, C. et al. Eicosanoid regulation of angiogenesis: Role of endothelial arachidonate 12-lipoxygenase. Blood 2000, 95: 2304-11.
32. Gao, X., Grignon, D.J., Chbihi, T. et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 1995, 46: 227-37.
33. Gupta, S., Srivastava, M., Ahmad, N. et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42: 73-8.
34. Kirschenbaum, A., Klausner, A.P., Lee, R. et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000, 56: 671-6.
35. Yoshimura, R., Sano, H., Masuda, C. et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000, 89: 589-96.
36. Liu, X.H., Kirschenbaum, A., Yao, S. et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000, 164: 820-5.
37. Hsu, A.L., Ching, T.T., Wang, D.S. et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275: 11397-403.
38. Narayanan, B.A., Condon, M.S., Bosland, M.C. et al. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: Effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 2003, 9: 3503-13.
39. Yoshimura, R., Matsuyama, M., Kawahito, Y. et al. The effect of cyclooxygenase-2 inhibitors on urological cancer cells. Int J Mol Med 2004, 13: 665-8.